October 25, 2021
Philanthropists Richard and Carol Dean Hertzberg have committed $2.1 million to develop and maintain the Dean-Hertzberg Breast Cancer Database System Initiative at UC San Diego Health Moores Cancer Center to support the work of Anne Wallace, MD and her collaborators at Moores Cancer Center.
July 20, 2017
…to University of California San Diego School of Medicine researchers to develop a new immunotherapy in which patients’ cells would be equipped with a special receptor that recognizes and targets cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.
May 6, 2019
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
February 27, 2018
…in the February 27 online issue of Science Signaling, researchers at University of California San Diego School of Medicine and Moores Cancer Center describe how a signaling protein that normally suppresses tumors can be manipulated (or re-programmed) by growth factors, turning it into a driver of malignant growth and metastasis.
August 5, 2013
A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.
April 15, 2021
Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s (PanCAN) newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
September 16, 2013
Cancer tumors almost never share the exact same genetic mutations, a fact that has confounded scientific efforts to better categorize cancer types and develop more targeted, effective treatments. Researchers at the University of California, San Diego propose a new approach called network-based stratification, which identifies cancer subtypes not by the…
December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the…
October 20, 2015
…most common types of cancer. This important drug has now been shown to play an unexpected role in blocking one of the pathways most commonly involved in driving the growth of cancers, according to a recent study by researchers at the San Diego Supercomputer Center (SDSC) as well as the…
December 8, 2020
Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas — the type of tumors that include prostate, breast, lung and colorectal cancers — even in the absence of known risk factors, such as genetic predisposition or tobacco use.
